Company research
ArriVent BioPharma, Inc.
CIK 1868279Updated Nov 11, 2026
AVBP price & chart
Loading TradingView…
NASDAQ:AVBP on TradingView ↗About the company
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of next-generation antibody drug conjugates, through approval and commercialization.
In the news
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 2.02, 5.02, 9.01
SCHEDULE 13G/A - filed by FMR LLC regarding ArriVent BioPharma, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13D/A - filed by ORBIMED ADVISORS LLC regarding ArriVent BioPharma, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition
Items 1.01, 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 326,555,000Source | 292,711,000Source | 394,718,000Source | 269,506,000Source | 308,855,000Source | 349,295,000Source | 215,495,000Source | 327,838,000Source | 333,169,000Source | 274,942,000Source | 163,098,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 112,672,000Source | 282,855,000Source | 154,682,000Source | 112,765,000Source | 298,669,000Source | 62,103,000Source | 49,865,000Source | 317,393,000Source | 45,540,000Source | 74,293,000Source | 150,389,000Source |
| Assets, CurrentUSD | 321,218,000Source | 292,398,000Source | 394,173,000Source | 250,149,000Source | 308,511,000Source | 348,700,000Source | 185,785,000Source | 327,480,000Source | 332,897,000Source | 226,979,000Source | 159,968,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 20,952,000Source | 9,543,000Source | 21,054,000Source | 14,462,000Source | 9,842,000Source | 22,320,000Source | 9,708,000Source | 10,087,000Source | 20,076,000Source | 8,116,000Source | 9,579,000Source |
| Operating Lease, Right-of-Use AssetUSD | 49,000Source | 187,000Source | 370,000Source | 85,000Source | 219,000Source | 370,000Source | 120,000Source | 250,000Source | 13,000Source | 154,000Source | 291,000Source |
| Other Assets, NoncurrentUSD | 180,000Source | 126,000Source | 134,000Source | 479,000Source | 125,000Source | 156,000Source | 176,000Source | 108,000Source | 190,000Source | 126,000Source | 107,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 21,558,000Source | 15,218,000Source | 27,877,000Source | 19,636,000Source | 12,196,000Source | 25,315,000Source | 12,953,000Source | 10,115,000Source | 25,945,000Source | 17,288,000Source | 11,801,000Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 5,000Source | 4,000Source | 3,000Source | 5,000Source | 4,000Source | 3,000Source | 4,000Source | 3,000Source | — |
| Additional Paid in CapitalUSD | 673,884,000Source | 495,190,000Source | 864,957,000Source | 584,003,000Source | 493,792,000Source | 772,206,000Source | 505,275,000Source | 492,982,000Source | 711,847,000Source | 496,195,000Source | 4,652,000Source |
| Retained Earnings (Accumulated Deficit)USD | -369,097,000Source | -217,700,000Source | -497,854,000Source | -334,119,000Source | -197,136,000Source | -447,961,000Source | -302,720,000Source | -175,262,000Source | -404,641,000Source | -238,333,000Source | -157,845,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 206,000Source | — | -267,000Source | -18,000Source | — | -270,000Source | -17,000Source | — | 14,000Source | -211,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 304,997,000Source | 277,493,000Source | 366,841,000Source | 249,870,000Source | 296,659,000Source | 323,980,000Source | 202,542,000Source | 317,723,000Source | 307,224,000Source | 257,654,000Source | -153,193,000Source |
| Liabilities and EquityUSD | 326,555,000Source | 292,711,000Source | 394,718,000Source | 269,506,000Source | 308,855,000Source | 349,295,000Source | 215,495,000Source | 327,838,000Source | 333,169,000Source | 274,942,000Source | 163,098,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 21,558,000Source | 15,162,000Source | 27,844,000Source | 19,636,000Source | 12,098,000Source | 24,995,000Source | 12,953,000Source | 9,977,000Source | 25,945,000Source | 17,274,000Source | 11,624,000Source |
| Operating Lease, Liability, CurrentUSD | 56,000Source | 157,000Source | 318,000Source | 98,000Source | 152,000Source | 99,000Source | 138,000Source | 147,000Source | 14,000Source | 162,000Source | 140,000Source |
| Accounts Payable, CurrentUSD | 5,933,000Source | 4,646,000Source | 2,217,000Source | 4,060,000Source | 3,812,000Source | 8,727,000Source | 4,364,000Source | 4,098,000Source | 5,934,000Source | 3,782,000Source | 4,532,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 56,000Source | 33,000Source | — | 98,000Source | 320,000Source | — | 138,000Source | — | 14,000Source | 177,000Source |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | 15,569,000Source | 10,359,000Source | 25,309,000Source | 15,478,000Source | 8,134,000Source | 16,169,000Source | 8,451,000Source | 5,732,000Source | 19,997,000Source | 13,330,000Source | 6,952,000Source |
| Short-term InvestmentsUSD | 187,594,000Source | — | 218,437,000Source | 122,922,000Source | — | 264,277,000Source | 126,212,000Source | — | 267,281,000Source | 144,570,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -43,320,000Source | -64,387,000Source | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,485,000Source | 2,271,000Source | 12,520,000Source | 3,208,000Source | 895,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -41,892,000Source | -68,008,000Source | -160,588,000Source | -70,212,000Source | -55,842,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 3,582,000Source | 36,821,000Source | -71,228,000Source | -192,465,000Source | — |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 54,873,000Source | 6,759,000Source | 203,063,000Source | 186,581,000Source | 42,859,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 16,563,000Source | -24,428,000Source | -28,753,000Source | -76,096,000Source | -12,983,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 112,672,000Source | 282,855,000Source | 154,682,000Source | 112,765,000Source | 62,103,000Source | 49,865,000Source | 45,540,000Source | 74,293,000Source | 150,389,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,716,000Source | 865,000Source | 6,665,000Source | 3,311,000Source | 5,485,000Source | 2,271,000Source | 12,520,000Source | 3,208,000Source | 895,000Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | -559,000Source | — | -3,026,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 6,149,000Source | 4,144,000Source | 10,352,000Source | 5,903,000Source | 8,494,000Source | 5,483,000Source | 24,183,000Source | 15,304,000Source | 9,706,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,978,000Source | -20,564,000Source | -49,893,000Source | -31,399,000Source | -43,320,000Source | -64,387,000Source | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -34,978,000Source | -20,564,000Source | -49,893,000Source | -31,399,000Source | -43,320,000Source | -64,387,000Source | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Operating ExpensesUSD | — | — | 38,316,000Source | 24,232,000Source | 52,691,000Source | 33,623,000Source | 46,111,000Source | 66,772,000Source | 177,534,000Source | 94,308,000Source | 74,590,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 200,000Source | 200,000Source | 200,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 64,383,000Source | 9,817,000Source | 272,934,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 54,724,000Source | 6,516,000Source | 202,631,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 149,000Source | 293,000Source | 502,000Source | 631,000Source | 354,000Source |
| Investment Income, Interest | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -38,316,000Source | -24,232,000Source | -52,691,000Source | -33,623,000Source | -46,111,000Source | -66,772,000Source | -177,534,000Source | -94,308,000Source | -74,590,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,978,000Source | -20,564,000Source | -49,893,000Source | -31,399,000Source | -43,320,000Source | -64,387,000Source | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.83Source | -0.61Source | -1.05Source | -0.9Source | -0.96Source | -1.9Source | -4.32Source | -2.56Source | -32.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.83Source | -0.61Source | -1.05Source | -0.9Source | -0.96Source | -1.9Source | -4.32Source | -2.56Source | -32.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 41,912,905Source | 33,581,810Source | 47,606,857Source | 35,006,114Source | 45,067,658Source | 33,898,870Source | 38,462,600Source | 31,469,328Source | 2,140,951Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 41,912,905Source | 33,581,810Source | 47,606,857Source | 35,006,114Source | 45,067,658Source | 33,898,870Source | 38,462,600Source | 31,469,328Source | 2,140,951Source |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 6,149,000Source | 4,144,000Source | 10,352,000Source | 5,903,000Source | 8,494,000Source | 5,483,000Source | 24,183,000Source | 15,304,000Source | 9,706,000Source |
| Investment Income, NetUSD | — | — | 3,338,000Source | 3,668,000Source | 2,798,000Source | 2,224,000Source | 2,791,000Source | 2,385,000Source | 11,226,000Source | 13,820,000Source | 5,257,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -34,978,000Source | -20,564,000Source | -49,893,000Source | -31,399,000Source | -43,320,000Source | -64,387,000Source | -166,308,000Source | -80,488,000Source | -69,333,000Source |
| Operating ExpensesUSD | — | — | 38,316,000Source | 24,232,000Source | 52,691,000Source | 33,623,000Source | 46,111,000Source | 66,772,000Source | 177,534,000Source | 94,308,000Source | 74,590,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 200,000Source | 200,000Source | 200,000Source |
| Research and Development ExpenseUSD | — | — | 32,167,000Source | 20,088,000Source | 42,339,000Source | 27,720,000Source | 37,617,000Source | 61,289,000Source | 153,351,000Source | 79,004,000Source | 64,884,000Source |
| Investment Income, Interest | — | — | — | —Source | — | — | — | — | — | — | — |
Filing attachments
tm2629343d1_ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO Dosed first patient in U.S. Phase 1a/1b study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, with initial focus in ovarian and endometrial cancers Strengthened clinical leadership with announcement of …
Read attachment ↗tm2628237d1_ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program ───────────────────────────────────────────────────────────────────────────── NEWTOWN SQUARE, PA, October 25, 2026 (GLOBE NEWSWIRE…
Read attachment ↗tm2627799d1_ex99-1.htm · 8-K · 2026-10-19
Exhibit 99.1 ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighti…
Read attachment ↗tm2627450d1_ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaP…
Read attachment ↗tm2627092d1_ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC NEWTOWN SQUARE, PA, October 6, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with…
Read attachment ↗tm2622880d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622880d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2026 Financial Results Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial c…
Read attachment ↗